




RealRate

PHARMACEUTICAL 2020

Syros Pharmaceuticals Inc.
Rank 99 of 358





RealRate

PHARMACEUTICAL 2020

Syros Pharmaceuticals Inc. Rank 99 of 358



The relative strengths and weaknesses of Syros Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syros Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Syros Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 126% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	114,513
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,516
Liabilities, Non-Current	0
Other Assets	20,255
Other Compr. Net Income	2,330
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	1,982
Property and Equipment	15,210
Research and Development	58,245
Selling, General and Administrative Expense	21,478

Output Variable	Value in 1000 USD
Assets	149,978
Liabilities	23,516
Expenses	79,723
Revenues	1,982
Stockholders Equity	126,462
Net Income	-77,741
Comprehensive Net Income	-76,576
Economic Capital Ratio	162%